$25.44
-0.06 (-0.24%)
NRIX News2 articles
Nurix Surges on Roche's $2.3B Cancer Drug Pact
Nurix shares soared premarket after Roche committed up to $2.3 billion for bexobrutideg, with $700 million upfront, validating the BTK degrader ahead of Phase 3 trials.
Roche Shares Inch Up on $2.3B Nurix Deal for Blood Cancer Drug
Roche shares gained 1.07% on a $2.3 billion deal with Nurix for bexobrutideg, a late-stage BTK degrader for CLL, set to enter Phase 3 this summer.